p38 MAPK Inhibitor
≥98%
- Product Code: 62563
CAS:
219138-24-6
| Molecular Weight: | 365.8 g./mol | Molecular Formula: | C₂₀H₁₃ClFN₃O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
P38 MAPK inhibitors are primarily used in research and therapeutic contexts to modulate inflammatory responses and cellular stress pathways. In biomedical research, they are valuable tools for studying the role of p38 MAPK signaling in diseases such as cancer, autoimmune disorders, and neurodegenerative conditions. By inhibiting this pathway, researchers can better understand its contribution to disease progression and identify potential therapeutic targets.
In clinical applications, p38 MAPK inhibitors are being explored as potential treatments for inflammatory diseases like rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). They work by reducing the production of pro-inflammatory cytokines, thereby alleviating inflammation and associated symptoms.
Additionally, these inhibitors are investigated for their potential in treating certain cancers, as p38 MAPK signaling can promote tumor growth and metastasis. By blocking this pathway, they may help slow cancer progression or enhance the efficacy of other cancer therapies.
Overall, p38 MAPK inhibitors hold significant promise in both research and therapeutic development, particularly in addressing inflammation-related diseases and cancer.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿39,978.00 |
+
-
|
p38 MAPK Inhibitor
P38 MAPK inhibitors are primarily used in research and therapeutic contexts to modulate inflammatory responses and cellular stress pathways. In biomedical research, they are valuable tools for studying the role of p38 MAPK signaling in diseases such as cancer, autoimmune disorders, and neurodegenerative conditions. By inhibiting this pathway, researchers can better understand its contribution to disease progression and identify potential therapeutic targets.
In clinical applications, p38 MAPK inhibitors are being explored as potential treatments for inflammatory diseases like rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). They work by reducing the production of pro-inflammatory cytokines, thereby alleviating inflammation and associated symptoms.
Additionally, these inhibitors are investigated for their potential in treating certain cancers, as p38 MAPK signaling can promote tumor growth and metastasis. By blocking this pathway, they may help slow cancer progression or enhance the efficacy of other cancer therapies.
Overall, p38 MAPK inhibitors hold significant promise in both research and therapeutic development, particularly in addressing inflammation-related diseases and cancer.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :